Vertex Reports long-term follow-up Data for Blinatumomab in Multiple sclerosis

Vertex today announced long-term follow-up results for blinatumomab in patients with multiple sclerosis. The study demonstrated that blinatumomab reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of multiple sclerosis and support the continued development of blinatumomab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.